State
Synopsis: State SBIR-STTR Data
M&A Deals
379Firms with IP
1,374Total US patents
45,182Awards Distribution by Agency (over life of program)
Trending State Award Dollars (5-yr increments)
Extent of SBIR involvement
Most Recent SBIR Projects
| Title | Year | Agency | $$$ | Firm | |||
|---|---|---|---|
| Targeting Type 3 Diabetes (T3D) Mechanism of Alzheimer's Disease (AD) and AD-Related Dementias | |||
| 2025 | NIH | $249,995 | ReGENE LLC |
| Modular Autonomous Capability for Landing on Uncooperative Vehicles (MACLUV) | |||
| 2025 | Navy | $999,802 | GreenSight Agronomics |
| Revolutionized Undersea Training Target Motors | |||
| 2025 | Navy | $683,411 | Triton Systems Inc |
Featured SBIR Firm
BYOmass IncBYOMass Inc. is a preclinical metabolic disease biotech structured around development of therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses. In metabolic disease space, the focus / target is primarily on tissues - liver, muscle and pancreas. BYOmass principals indicate their focus will instead be focusing on how the brain controls metabolism - "more specifically ,how the hypothalamus... see more
|
|
| no website avail. | (860) 501-1575 | |
State
Synopsis: State SBIR-STTR Data
M&A Deals
24Firms with IP
426Total US patents
8,732State Data & Analysis
Click on the map OR choose State from menu below
Awards Distribution by Agency (last 5 years)
Trending State Award Dollars (5-yr increments)
Extent of SBIR involvement
Most Recent SBIR Projects
| Title | Year | Agency | $$$ | Firm | |||
|---|---|---|---|
| Targeting Type 3 Diabetes (T3D) Mechanism of Alzheimer's Disease (AD) and AD-Related Dementias | |||
| 2025 | NIH | $249,995 | ReGENE LLC |
| Modular Autonomous Capability for Landing on Uncooperative Vehicles (MACLUV) | |||
| 2025 | Navy | $999,802 | GreenSight Agronomics |
| Revolutionized Undersea Training Target Motors | |||
| 2025 | Navy | $683,411 | Triton Systems Inc |
Featured SBIR Firm
|
BYOmass Inc BYOMass Inc. is a preclinical metabolic disease biotech structured around development of therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses. In metabolic disease space, the focus / target is primarily on tissues - liver, muscle and pancreas. BYOmass principals indicate their focus will instead be focusing on how the brain controls metabolism - "more specifically ,how the hypothalamus... see more
|
|
| no website avail. | (860) 501-1575 | |
